Drug intelligence / Profile preview

PGP-0807

Development stage: Preclinical
Lead developer: ProGenis Pharmaceuticals

Overview

PGP-0807 is an investigational therapeutic candidate currently in preclinical development by ProGenis Pharmaceuticals. It is being studied for the treatment of liver fibrosis. As of early 2026, the program remains in the preclinical phase, and the sponsor has not publicly disclosed specific details regarding the drug's chemical modality (e.g., small molecule, monoclonal antibody) or its exact molecular target and mechanism of action.

Beyond the preview

Go deeper on PGP-0807.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PGP-0807.